The FDA’s trio of recent roadmaps attempt to unify and streamline their previously fractured and siloed strategies through a metrics-driven approach that prizes low-code and no-code platforms.

Businesses need to deal with new regulatory hurdles and obstacles. Luckily, they know how to move forward fast: low-code/no-code solutions.

That represents a big business opportunity for the likes of Gyana, which has been unique in using the no-code approach specifically to tackle the area of data science.